SEX AND PERMANENT DRUG DISCONTINUATION IN CLINICAL TRIALS: INSIGHTS FROM THE TIMI TRIALS

Emily Lau,Eugene Braunwald,David A. Morrow,Robert Giugliano,Elliott M. Antman,C. Michael Gibson,Benjamin M. Scirica,Erin Ann Bohula,Deepak Bhatt,Christopher P. Cannon,KyungAh Im,Jianping Guo,Marc Steven Sabatine,Michelle O’Donoghue
DOI: https://doi.org/10.1016/s0735-1097(20)34133-4
IF: 24
2020-01-01
Journal of the American College of Cardiology
Abstract:Women are underrepresented across cardiovascular clinical trials. Whether women are more likely than men to prematurely discontinue study drug is unknown. Eleven phase 3 TIMI trials were included [135,879 men and 51,812 women (28%)]. The association between sex and odds of premature study drug
What problem does this paper attempt to address?